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ABSTRACT
Sunitinib (SU11248) is an orally bioavailable inhibi-
tor that affects the receptor tyrosine kinases involved
in tumour proliferation and angiogenesis, including
vascular endothelial growth factor (VEGF) receptors
1, 2, 3, and platelet-derived growth factor receptors
alpha (PDGFRA) and beta (PDGFRB). Because angiogen-
esis is necessary for the growth and metastasis of solid
tumours, and VEGF is believed to have a pivotal role
in that process, sunitinib treatment may have broad-
spectrum clinical utility. In the present article, we
discuss the biologic and clinical rationales that have
recently led the Investigational New Drug Program
of the National Cancer Institute of Canada Clinical
Trials Group to initiate four phase II trials testing this
agent in the following four different tumour types:
relapsed diffuse large cell lymphoma, malignant pleu-
ral mesothelioma, locally advanced or metastatic cer-
vical cancer and recurrent epithelial ovarian, fallopian
tube, or primary peritoneal carcinoma.
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1. INTRODUCTION
Significant preclinical and clinical research in oncol-
ogy is focused on targeting malignant angiogenesis,
because angiogenesis is common to most tumours
and may contribute to disease pathogenesis and
propagation. Numerous agents are currently under
development. One class of anti-angiogenic agents
includes the multi-targeted receptor tyrosine kinase
inhibitors. Agents within this class often inhibit more
than one of the receptors that initiate the intracellular
signalling that culminates in an angiogenic pheno-
type. Sunitinib is one such agent. In the present ar-
ticle, we discuss the biologic and clinical rationales
that have recently led the Investigational New Drug
(IND) Program of the National Cancer Institute of
Canada Clinical Trials Group (NCIC CTG) to initiate
four phase II trials testing this agent in four different
tumour types.
Expression by tumours of vascular endothelial
growth factor (VEGF) has been associated clinically
with disease prognosis in many different types of
malignancies. This expression is increased by diverse
stimuli, including proto-oncogene activation and hy-
poxia, with the hypoxic state frequently arising in
solid tumours because of inadequate perfusion. In
addition to its angiogenic role, VEGF also profoundly
increases the permeability of the vasculature, thereby
potentially contributing to tumour progression, be-
cause a leaky tumour endothelium enhances nutri-
ent and catabolite exchange and lowers barriers to
tumour cell migration and extravasation during
metastasis.
Two high-affinity receptors for VEGF with associ-
ated tyrosine kinase activity have been identified on
human vascular endothelium: VEGFR1/FLT1 and
VEGFR2/kinase insert domain-containing receptor. In-
creasing evidence implicates not only VEGF receptor
signalling, but also platelet-derived growth factor
receptor (PDGFR) signalling in tumour angiogenesis.
Recent preclinical evidence suggests that inhibition
of PDGFR signalling augments the antitumour and anti-
angiogenic effects of VEGFR inhibitors 1. In addition,
PDGFR signalling is implicated in the autocrine growth
of tumour cells and in the recruitment and regulation
of tumour fibroblasts.
2. SUNITINIB
Sunitinib (SU11248) it is an orally bioavailable in-
hibitor that affects the receptor tyrosine kinases in-
volved in tumour proliferation and angiogenesis,
including VEGF receptors 1, 2, 3, and PDGFRA and
PDGFRB. The demonstrated activity of sunitinib in gas-
trointestinal stromal tumours (GIST) 2, acute myeloid
leukemia (AML) 3, and renal cell carcinoma (RCC) 4 may
be at least in part mediated by its anti-angiogenic ef-
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fects—although in some of these instances, effects
on other tyrosine kinases may also play a role.
With chronic oral dosing, sunitinib is expected
to inhibit PDGF- and VEGF-driven angiogenesis and, as
a consequence, to limit solid tumour growth. Because
angiogenesis is necessary for the growth and metasta-
sis of solid tumours, and VEGF is believed to have a
pivotal role in that process, sunitinib treatment may
have broad-spectrum clinical utility 5,6. Sunitinib also
exerts direct antitumour activity on cells that express
target receptor tyrosine kinases associated with tu-
mour cell proliferation, such as Kit, PDGFR, and Ret.
Phase I testing of sunitinib has demonstrated
single-agent activity in patients with RCC, GIST, non-
GIST sarcomas, non-small cell lung cancer, colorectal
cancer, neuroendocrine tumours, melanoma, prostate
cancer, and thyroid cancer. Phase I testing in patients
with AML has been completed. Phase II and III testing
have included single-agent trials in metastatic RCC,
imatinib-resistant GIST, metastatic breast cancer, non-
small cell lung cancer, and carcinoid and islet cell
neuroendocrine tumours. Results of some of these
trials have led to approval of sunitinib for specific
indications by the U.S. Food and Drug Administra-
tion. The most promising results have included a re-
port of phase II testing in patients with metastatic RCC:
among 63 patients, 25 (40%) achieved a partial re-
sponse (PR) as determined by the Response Evalua-
tion Criteria in Solid Tumors (RECIST), and an
additional 17 (27%) had stable disease (SD) for
³ 3 months. In a multinational, randomized, double-
blind, placebo-controlled phase III trial that included
more than 300 patients with imatinib-resistant GIST,
results of an interim analysis demonstrated a median
time-to-progression of 27.3 weeks in the sunitinib
arm as compared with 6.4 weeks in the placebo group
(p < 0.001) 2. Based on these results, and in response
to a solicitation for studies by the Cancer Therapy
Evaluation Program of the U.S. National Cancer In-
stitute, the IND Program of the NCIC CTG has initiated
separate phase II trials testing sunitinib in patients with
progressive diffuse large B cell lymphoma, malignant
pleural mesothelioma, locally advanced or metastatic
carcinoma of the cervix, and recurrent carcinoma of
the ovary (including fallopian tube and primary peri-
toneal carcinoma).
3. RATIONALE FOR ANGIOGENESIS
INHIBITORS
3.1 Diffuse Large B Cell Lymphoma
Anthracycline-based chemotherapy with cyclophos-
phamide, doxorubicin, vincristine, and prednisone
(CHOP) remains the standard of care for most patients
with aggressive-histology lymphoma 7. Although the
addition of rituximab (CHOP-R) has improved survival
in the primary treatment of diffuse large B cell lym-
phoma (DLBCL) 8, the management of relapsed and
refractory lymphomas remains problematic. Autolo-
gous stem cell transplantation has a well-defined role
in a limited number of patients who are of an appro-
priate age and who demonstrate chemosensitivity
before transplantation 9. Unfortunately, most patients
with aggressive-histology lymphomas who relapse
after autologous transplantation succumb rapidly to
their disease; median overall survival ranges from
3 months to 7.7 months  10,11. Traditional palliative
chemotherapy is associated with short rates of pro-
gression-free and overall survival 12–14. Newer thera-
pies may provide useful options for patients who are
not eligible for, or who are unresponsive to, stem cell
transplantation, given that no standard of care exists
for these patients.
Preclinical and clinical data that are now avail-
able support the important role of tumour angiogenic
growth factors and angiogenesis in the pathogenesis
and prognosis of lymphoma 15,16; VEGF and VEGFR are
present in lymphoma cells and angiogenesis-associ-
ated parameters are important prognosticators 17.
Murine models of DLBCL xenografts respond to treat-
ment with antibodies to VEGFR1 and 2, supporting the
presence of autocrine VEGFR1– and paracrine VEGFR2–
mediated pathways in lymphomagenesis 18 .
Endostatin, an anti-angiogenic drug, induced tumour
stabilization or regression (or both) after chemo-
therapy or anti-CD20 therapy in a NOD/SCID mouse
model of human high-grade lymphoma 19. A trial of
the VEGF antibody, bevacizumab, in relapsed aggres-
sive-histology lymphoma showed some modest ac-
tivity (PR = 5% and SD = 20%), with a relationship
between  VEGF and VEGFR expression suggesting a pos-
sible autocrine pathway in some patients 20, which is
consistent with preclinical models 18. These results
have led to phase II combination studies of bevaci-
zumab with CHOP and CHOP-R and a phase III study
comparing CHOP-R with or without bevacizumab for
newly diagnosed patients with DLBCL is in its initial
stages.
Furthermore, independent research undertaken at
some NCIC CTG centres demonstrated a response rate
of 37% and a SD rate of 20% in 32 heavily pretreated
patients with relapsed and refractory aggressive non-
Hodgkin lymphoma using anti-angiogenic “metro-
nomic” oral chemotherapy (cyclophosphamide 50 mg
daily) and high-dose celecoxib 800 mg daily. One
third of these patients had disease progression after
autologous transplantation 21. The median response
duration was 8.5 months and 5 patients had responses
lasting from 12 to 26 months or more. In this trial,
circulating endothelial cells (CECs) and circulating
endothelial cell progenitors (CEPs) declined in patients
responding to treatment. In the bevacizumab study
referenced earlier 20, CECs and plasma VEGF declined
during therapy, but no relationship to response was
described.
These data provide a rationale for studying other
VEGF- and VEGFR-targeted agents in DLBCL. EvaluationPHASE II TESTING OF SUNITINIB
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of CECs and CEPs would be logical correlative ques-
tions to be included in such testing.
3.2 Malignant Pleural Mesothelioma
Malignant pleural mesothelioma is an unusual malig-
nancy. Approximately 400 new cases are diagnosed
annually in Canada 22, and 2000–3000 new cases an-
nually in the United States 23. The disease is commonly
associated with earlier asbestos exposure. A prepon-
derance of patients are not candidates for surgical
therapy, because they present with locoregionally ad-
vanced disease or are not medically suitable for such
therapy. These patients are treated with palliative in-
tent. Cisplatin-based chemotherapy is the treatment
of choice, but median survival is only 12 months. No
data describing benefits of chemotherapy for patients
with progressive disease following cisplatin-based
therapy are available. Additionally, many patients are
not medically suitable for platinum-based treatment,
or they decline the option. Clearly, new agents are
needed in this disease.
Recent reports in the literature have suggested a
link between angiogenesis and prognosis in malig-
nant mesothelioma. Mesothelioma tumours and cell
lines have been found to express VEGF ligands 24,25,
which could contribute to tumour-associated angio-
genesis and lymphangiogenesis. In addition to VEGF
ligands, mesothelioma tumours and cell lines have
also been shown to express the receptors for VEGF
ligands 24–27, suggesting that mesothelioma tumour
cells may respond to VEGF in an autocrine and para-
crine manner. Additionally, an autocrine growth
stimulatory effect of PDGF via PDGFR may play a role
in the disease pathogenesis and in the metastatic po-
tential. Because angiogenesis is felt to be important
in the pathogenesis of mesothelioma, there is a good
rationale for the use of anti-angiogenesis agents in
this cancer.
3.3 Locally Advanced or Metastatic Cervical Cancer
Carcinoma of the cervix is the second most common
malignancy in women after breast cancer. With the
introduction of Papanicolaou smear screening pro-
grams, the incidence and mortality have decreased,
but approximately 200,000 women worldwide still
die from their disease each year 28.
Based on the results of several phase III studies,
standard approaches for many patients include poten-
tially curative treatment using primary radiotherapy
and concurrent platinum-based chemotherapy. Long-
term survival is approximately 85% for patients with
T1 disease, 70% for those with T2 disease, and 40%
for those with T3 disease 29. However, even with the
best currently available treatment, a significant pro-
portion of patients will experience recurrence and
eventually die. Some patients present with extensive
disease that is not amenable to curative locoregional
therapy, and in others, complete disease eradication
is never achieved. The median survival of patients with
advanced disease is only 9 months 30.
A number of chemotherapeutic agents have
shown activity in advanced and metastatic cervical
cancer, including cisplatin 31,32, paclitaxel 33, ifosfa-
mide 34, and topotecan 35. As compared with single–
agent cisplatin, treatment with cisplatin-based
combination chemotherapy improves survival, but
with very modest gains and increased toxicity 30.
Responses to second-line chemotherapy are infre-
quent. The poor outlook for these patients warrants
the development of novel therapeutic strategies that
exploit abnormal tumour biology as a means of im-
proving patient outcome. Furthermore, with the adop-
tion of platinum-based chemoradiation as a standard
of care for locally advanced disease, the search for
non-platinum based therapy is essential.
Overexpression of VEGF in adenocarcinomas of
the cervix suggests that VEGF is involved in tumour
angiogenesis in this histologic subtype 36. One study
suggested that higher pretreatment levels of VEGF and
VEGF-C in patients with squamous cell carcinomas of
the cervix correlated with poor outcome 37. A phase II
trial of bevacizumab (GOG 227A) in cervix cancer
is currently under way, and although the data have
not undergone complete analysis, the study has met
endpoints for the first phase of accrual, and the sec-
ond phase has been opened. Human papilloma virus–
associated cervical cancer–derived cell lines
co-express c-Kit and its ligand stem cell factor. These
molecules are important determinants of cell survival
and cell–cell interaction. Other receptor tyrosine ki-
nases have also been implicated in the development
and progression of cervical carcinoma. Given the poor
outlook for patients with advanced cervical cancer
and the central role played by receptor tyrosine ki-
nases in tumour proliferation and angiogenesis, it
would therefore be rational to test a novel, multi-tar-
geted inhibitor of angiogenesis in patients with
unresectable, locally advanced or metastatic cervical
carcinoma.
3.4 Recurrent Epithelial Ovarian, Fallopian Tube,
and Primary Peritoneal Carcinoma
Ovarian cancer is the leading cause of gynecologic
cancer deaths in North America. In 2005, an esti-
mated 22,000 and 2400 women were diagnosed with
this disease in the United States and Canada respec-
tively; at least 70% would be expected to die of their
disease 38.
Standard initial treatment includes debulking sur-
gery followed by combination chemotherapy that
includes a platinum drug and a taxane 39. Patients
with primary peritoneal carcinomatosis and advanced
fallopian tube cancers are generally managed in a
comparable manner; thus, these patients are com-
monly included in clinical trials evaluating therapiesBUCKSTEIN et al.
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for ovarian cancer. Despite aggressive primary man-
agement, most patients with ovarian cancer will re-
lapse and die of their disease. Systemic
chemotherapy for relapsed or refractory disease can
have important palliative effects, but treatment is not
curative 40. An important determinant of survival in
recurrent ovarian cancer is the platinum-free inter-
val (PFI), which is the time from completion of ini-
tial platinum-based therapy to first evidence of
recurrence 41. Patients with a PFI of at least 6 months
have a higher likelihood of response to second thera-
pies and superior survival 42. Importantly, clinicians
and patients must balance chemotherapy toxicities
with quality of life considerations when considering
treatment for relapsed or refractory disease. Novel
and more promising systemic treatment options are
required.
Indicators of enhanced angiogenesis, such as cir-
culating levels of VEGF and tissue microvessel den-
sity, have been correlated with the presence of
metastasis and survival in ovarian cancer 43. The VEGF
signalling pathway appears to contribute to growth
and progression in 80% or more of all ovarian can-
cers 44, and PDGF and its receptor pathway have also
been implicated in disease progression 45. Hence, tar-
geted therapies against angiogenesis signalling path-
ways may interrupt malignant growth potential. This
proof of principle has been established through ob-
servations of antitumour activity with the anti-VEGF
monoclonal antibody bevacizumab when used either
as a single agent in recurrent disease or in combina-
tion with low-dose metronomic chemotherapy 46–48.
On the basis of these initial clinical results, coupled
with a strong biologic rationale, and based on an
important need, priority must be given to an evalua-
tion of the activity of alternative angiogenesis inhibi-
tors for patients with ovarian cancer and related
diseases.
4. NCIC CTG IND TRIALS TESTING
SUNITINIB
Based on the strong biologic rationale linking angio-
genesis with disease progression, and with the prom-
ising results of sunitinib in treating RCC, GIST, and other
cancer types, the NCIC CTG, in conjunction with the
Cancer Therapy Evaluation Program of the U.S. Na-
tional Cancer Institute, has initiated four trials test-
ing this agent in the management of relapsed DLBCL
(IND.182); malignant pleural mesothelioma (IND.183);
squamous cell, adenosquamous, or adenocarcinoma
of the cervix (IND.184); and advanced or metastatic
epithelial ovarian, fallopian tube carcinoma, or pri-
mary peritoneal carcinoma (IND.185). All are non-
randomized, non-blinded, multicentre phase II trials.
Key objectives and inclusion and exclusion criteria
shared by all four trials are summarized in the next
few subsections, and Table I provides important
study-specific details.
Among the common objectives are these:
• Assess the efficacy and toxicity of sunitinib.
• Document response rates, objective progression
rates, and response durations.
• Assess dynamic biomarkers of angiogenesis in
select studies and centres.
The primary endpoint of each study is to deter-
mine the overall response defined by International
Workshop Criteria (for lymphoma) or RECIST (for cer-
vical and ovarian cancers), and the modified RECIST
criteria for mesothelioma 49. The design of each of
the trials includes common features such as the in-
clusion and exclusion criteria (Table II).
4.1 Safety Issues, Including Drug Interactions
The most frequent adverse events seen following
sunitinib treatment are constitutional (fatigue or as-
thenia), gastrointestinal (nausea, vomiting, diarrhea,
abdominal pain, anorexia, stomatitis, dysgeusia), and
hematologic (neutropenia, thrombocytopenia). Hand–
foot syndrome and skin discoloration are also seen 4.
Most of these adverse events are grades 1 and 2, but
at higher doses (75 mg), grades 3 and 4 fatigue or
asthenia were dose-limiting but readily reversible on
discontinuation of treatment 50. Tumour-related hem-
orrhage can occur with sunitinib, and in the case of
pulmonary tumours, it may present as severe and life-
threatening hemoptysis or pulmonary hemorrhage.
Sunitinib may induce asymptomatic mild declines
in left ventricular ejection fraction (LVEF) that are pri-
marily reversible upon drug reduction or discontinu-
ation. Infrequently (1.5%), grade 3 reductions in LVEF
have been seen in some trials, and symptomatic sys-
tolic dysfunction has been documented in 1% of pa-
tients. Because patients who presented with cardiac
events within 12 months before sunitinib adminis-
tration were excluded from clinical trials, whether
patients with these concomitant conditions may be at
higher risk of developing drug-related left ventricu-
lar dysfunction is unknown. Patients should be care-
fully monitored for signs of cardiac dysfunction, and
baseline and periodic evaluations of LVEF should be
performed in patients with risk factors for cardiac
disease such as prior anthracycline use or mediasti-
nal radiation (product monograph). Sunitinib has been
shown to prolong the QT interval in a dose-depen-
dent manner, which may lead to an increased risk for
ventricular arrhythmias such as torsade de pointes.
Torsade de pointes has been observed in <0.1% of
sunitinib-exposed patients. Sunitinib should be used
with caution in patients with a history of arrhythmias,
QT prolongation, pre-existing cardiac disease (prod-
uct monograph). Hypertension is a common side ef-
fect of this class of angiogenesis inhibitors, and
therefore strict guidelines for blood pressurePHASE II TESTING OF SUNITINIB
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monitoring and recommendations for antihyperten-
sive medications and dose reductions by grade are
indicated in the each of the four IND protocols. Each
protocol also includes dose attenuation schedules if
pre-specified toxicity criteria are observed.
Sunitinib malate is metabolized primarily by liver
enzymes, particularly CYP3A4. Thus, CYP3A4 in-
ducers—for example, rifampin, dexamethasone—and
CYP3A4 inhibitors—for example—grapefruit juice,
ketoconazole—should be avoided, and certain potent
inhibitors and inducers are contraindicated. Based on
clinical symptoms, dose reductions of the CYP3A4
inhibitors are recommended. Concomitant treatment
with dysrhythmic drugs—that is, terfenadine, quini-
dine, procainamide, disopyramide, sotalol, probucol,
bepridil, haloperidol, risperidone, indapamide, and
flecainide—is not recommended.
4.2 Assessment of Anti-angiogenic Activities
There is a strong rationale for evaluating circulating
endothelial cells (CECs) and circulating endothelial cell
progenitors (CEPs) as biomarkers of angiogenesis,
because the development of biomarkers that describe
TABLE I Study design for four prospective phase II studies using sunitinib by the National Cancer Institute of Canada Investigational New
Drug (IND) program
Study Design Sample size Specific inclusion criteria Dosing Treatment duration
IND 182 Dual-stage design Up to 25 1. Relapsed or refractory DLBCL 37.5 mg PO daily Up to 12 months
with 15 patients in stage 1 [includes thymic (mediastinal)] for 4-week cycles in patients achieving
 and 10 patients in stage 2 2. One to two prior continuously CR, PR, or SD
Drug active if ³3 responses chemotherapy regimens
(one of which must have been
doxorubicin-based) and
may have received one other
non-chemotherapy regimen
such as radiation
3. May be relapsed post ASCT
4. LVEF by MUGA > LLN
IND 183 Two-stage design— 1. Malignant pleural mesothelioma 50 mg PO daily Indefinite
Cohort 1: 16 patients in stage 1 Cohort 1: 2. Advanced or metastatic disease for 4 weeks for patients achieving
and 10 patients in stage 2 Up to 26 3. Two cohorts— of 6-week cycles CR, PR or SD
Drug active if ³5 responses cohort 1: previously treated,
Cohort 2: 17 patients in stage 1 Cohort 2: one prior cisplatin-containing regimen
and 15 patients in stage 2 up to 32 permitted, previous radiation and
Drug active if ³8 responses EGFR inhibitors
cohort 2: previously untreated
IND 184 Two-stage design with Up to 32 1. Squamous cell carcinoma 50 mg PO daily CR + 2 cycles
18 patients in stage 1 and 2. Adenosquamous carcinoma or for 4 weeks of Stable PR + 2 cycles
14 patients in stage 2 adenocarcinoma of the cervix 6-week cycles SD: up to 6 cycles
Drug active if ³4 responses 3. Unresected, locally advanced, or
metastatic disease
4. Neoadjuvant or adjuvant chemo-
therapy, concurrent chemoradiation
permitted
5. Up to one prior chemotherapy
regimen for recurrent metastatic disease
IND 185 Two-stage design with Up to 25 1. Epithelial ovarian carcinoma, 50 mg PO daily CR + 2 cycles
15 patients in stage 1 and fallopian tube carcinoma, or for 4 weeks of Stable PR + 2 cycles
10 patients in stage 2 primary peritoneal cancer 6 week cycles SD: up to 6 cycles
Drug active if ³3 responses 2. Advanced or metastatic
3. Minimum of one and




4. Up to one prior
hormonal therapy
DLBCL = diffuse large B cell lymphoma; PO = orally; CR = complete response; PR = partial response; SD = stable disease; ASCT = autologous
stem-cell transplant; LVEF = left ventricular ejection fraction; MUGA = multiple gated acquisition scan; LLN = lower limit of normal; EGFR =
epidermal growth factor receptor.BUCKSTEIN et al.
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the angiogenic profile of a tumour type and might
predict for response to anti-angiogenic agents car-
ries great potential 51,52. Resting and activated endo-
thelial cells are increased in the peripheral blood of
cancer patients 53 and may serve as more reliable sur-
rogate markers of angiogenesis than do soluble cir-
culating angiogenic growth factors and microvessel
density 54. In preclinical models, CECs and CEPs have
been found to be increased in lymphoma 55, in the
blood of breast cancer and lymphoma patients 53,56,
and in patients with myelodysplastic syndromes 57.
Recently, a number of investigators demonstrated that
CEPs (measured by four-colour flow cytometry) can
serve as biomarkers for angiogenic responsiveness
to VEGFR2 blocking antibody or a thrombospondin
mimetic peptide in several mouse strains 58. In addi-
tion, other preclinical studies have shown that other
anti-angiogenic agents, such as Endostatin (EntreMed
Rockville, MD, USA), caused reduced levels of CECs
and their CEP subset 59. Based on this background, and
the ability to capitalize on Canadian strengths in this
line of investigation through collaboration with
Shaked and colleagues 60, serial analysis of CECs and
CEPs will be included for selected patients in IND.182
testing of sunitinib in patients with DLBCL to assess
whether these biomarkers are predictive of response.
5. SUMMARY AND FUTURE DIRECTIONS
Sunitinib is an orally bioavailable inhibitor affecting
receptor tyrosine kinases involved in tumour prolif-
eration and angiogenesis. It has important antitumour
activity in patients with metastatic RCC and in patients
with  GIST who are resistant to imatinib. Given that
neoangiogenesis is virtually ubiquitous in cancer and
contributes to disease pathogenesis and propagation,
it is logical to test sunitinib in the four cancers de-
scribed earlier. If activity is demonstrated, future di-
rections would include developing appropriate
sunitinib-based combination regimens with chemo-
therapy or other targeted therapies for these malig-
nancies. Insights gained from serial CEC and CEP
measurements may help to identify patients likely to
respond and may validate the anti-angiogenic mecha-
nism of action of sunitinib.
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